A review of 115 randomized controlled trials involving more than 30,000 people found that escitalopram, duloxetine, and agomelatine were associated with greater likelihood of sustained response to treatment than fluoxetine over the long term. The study, published in The Lancet Psychiatry, also found that people taking escitalopram or duloxetine were less likely to drop out of trials than those taking fluoxetine.

Escitalopram is the most commonly prescribed antidepressant in Australia. Duloxetine ranks 45th among PBS-dispensed prescriptions, while agomelatine is not available on the PBS.

The researchers reviewed 115 trials and conducted a main analysis combining 35 trials that directly compared one antidepressant with another. They classified long-term use as six months or more.

However, the findings have significant limitations. More than half of the studies in the main analysis were assessed as having a high risk of bias, meaning "some of the differences between antidepressants may reflect limitations in the original studies rather than genuine differences between the medicines." Only six trials followed participants for longer than six months, leaving limited data on how effectiveness compares over extended periods. The average time people actually take antidepressants is much longer than the typical trial duration of around six months.

The results reflect average outcomes across groups and cannot predict which antidepressant will work best for any particular person. People respond differently to antidepressants, and acceptability involves trade-offs between symptom improvement, side effects, and impact on daily life.